Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited. Between February and October 2018, 274 HIV/HBV-coinfected participants who had achieved HIV RNA...

Full description

Saved in:
Bibliographic Details
Published in:Microbiology spectrum 2023-06, Vol.11 (3), p.e0512522
Main Authors: Huang, Yu-Shan, Cheng, Chien-Yu, Sun, Hsin-Yun, Cheng, Shu-Hsing, Lu, Po-Liang, Lee, Chen-Hsiang, Lee, Yuan-Ti, Tsai, Hung-Chin, Yang, Chia-Jui, Liu, Chun-Eng, Liou, Bo-Huang, Lin, Shih-Ping, Huang, Sung-Hsi, Ho, Mao-Wang, Tang, Hung-Jen, Hung, Chien-Ching
Format: Article
Language:English
Subjects:
Adenine - therapeutic use
Antimicrobial Chemotherapy
antiretroviral therapy
bone mineral density
Cholesterol
Cobicistat - therapeutic use
Coinfection - drug therapy
Creatinine
DNA, Viral
Emtricitabine - therapeutic use
Hepatitis B e Antigens - therapeutic use
Hepatitis B virus
hepatitis D virus
HIV Infections - complications
HIV Infections - drug therapy
Humans
hyperlipidemia
proximal renal tubulopathy
Research Article
RNA
Tenofovir - therapeutic use
viral hepatitis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited. Between February and October 2018, 274 HIV/HBV-coinfected participants who had achieved HIV RNA of
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.05125-22